Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Aging (NIA) GlaxoSmithKline |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00242593 |
The purpose of this study is to determine the effects of the insulin-sensitizing medication rosiglitazone on attention and memory skills in older adults with mild cognitive impairment (MCI). The study also will examine the effects of this medication on brain structures that support memory and other thinking abilities, and on biological markers associated with inflammation, insulin resistance, and cardiovascular disease.
Condition | Intervention | Phase |
---|---|---|
Mild Cognitive Impairment |
Drug: Rosiglitazone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | The Effects of Rosiglitazone on Cognition in Patients With MCI |
Estimated Enrollment: | 120 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
oral rosiglitazone 4 mg twice daily for 18 months
|
Drug: Rosiglitazone
4 mg twice daily oral rosiglitazone or placebo pill for 18 months
|
B: Placebo Comparator
placebo pill twice daily for 18 months
|
Drug: Rosiglitazone
4 mg twice daily oral rosiglitazone or placebo pill for 18 months
|
The study will examine the effects of the insulin-sensitizing agent rosiglitazone on learning and memory for 120 patients diagnosed with MCI.
Participants will be randomized to an 18-month trial of rosiglitazone or placebo, followed by a 2-month washout period. At screening and at treatment month 18, all participants will undergo an oral glucose tolerance test (OGTT) to estimate pre- and post- treatment insulin sensitivity and β-cell function. Cognitive measures and blood samples for biochemical assays will be obtained at baseline, treatment months 6, 12, and 18, and washout (two months after completing treatment).
During treatment, participants will have safety labs drawn and receive physical assessment of any adverse events, changes in health status, or changes in medication; initially these visits will be done at weeks 2 and 4, and then every three months. For months in which a safety visit is not scheduled, telephone monitoring to assess any health concerns will be conducted.
All participants enrolled in the primary study will be approached to participate in an MRI substudy; patients will undergo serial brain MRI before treatment and following 18 months of rosiglitazone or placebo, using three-dimensional T1-weighted images. Comparison of MCI patients receiving rosiglitazone and placebo will be conducted to determine whether the rate of medial temporal lobe (MTL) and whole brain atrophy is altered following treatment.
Ages Eligible for Study: | 55 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The following exclusion criteria will be used, based on initial physical examination, medical history, lab work, and oral glucose tolerance test (OGTT) results:
United States, Arizona | |
Banner Alzheimer Institute | |
Phoenix, Arizona, United States, 85006 | |
United States, California | |
UCLA Alzheimer's Disease Center | |
Los Angeles, California, United States, 90095 | |
United States, Washington | |
University of Washington/VA Puget Sound Health Care System | |
Seattle/Tacoma, Washington, United States, 98108 |
Principal Investigator: | Suzanne Craft, PhD | University of Washington/VA Puget Sound Health Care System |
Responsible Party: | University of Washington School of Medicine ( Suzanne Craft, PhD ) |
Study ID Numbers: | IA0087, 1RO1 AG025502-01A1 |
Study First Received: | October 19, 2005 |
Last Updated: | January 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00242593 History of Changes |
Health Authority: | United States: Federal Government |
cognition disorders Alzheimer's disease memory |
Hypoglycemic Agents Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease |
Dementia Rosiglitazone Cognition Disorders Delirium |
Hypoglycemic Agents Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Physiological Effects of Drugs |
Rosiglitazone Pharmacologic Actions Cognition Disorders |